Latest News

A post-hoc analysis of the ARISTOTLE trial demonstrated that patients with rectal cancer with high tumor cell density had improved DFS and OS.

Investigators will submit full results from the REZILIENT3 trial assessing zipalertinib in EGFR-mutated NSLCC at a future international medical meeting.

The primary end point of PFS-6 was met in the phase 2 NEO100-01 trial assessing NEO100 in patients with grade III/IV IDH1-mutant glioma.

Edward S. Kim, MD, MBA, explained how City of Hope leverages AI tools to help community oncologists match patients with multidisciplinary clinical trials.

Toxicity management for patients who receive CAR T-cell therapy for multiple myeloma is improving, according to Marco Davila, MD, PhD.

Yu-Wei Chen, MD, MS, discussed research on ARNT expression patterns in RCC and potential implications for HIF-1β targeting therapies like NEO-811.

Final DeFianCe trial results showed baseline plasma DKK1 predicts deepening sirexatamab benefit in second-line colorectal cancer.

Phase 1b study data show that izalontamab brengitecan produced a 48.1% objective response rate in previously treated extensive-stage small cell lung cancer.

Academic clinicians have an incumbent role to improve access to novel cellular therapies, according to Marco Davila, MD, PhD.

The FDA approved the PGDx elio tissue complete CDx to identify patients with advanced melanoma with BRAF V600E/K variants eligible for targeted therapy.

ARNT expression was consistent across RCC subtypes and was not associated with survival in a real-world analysis, according to Yu-Wei Chen, MD, MS.

In a phase 1 dose-escalation trial, duvelisib plus azacitidine produced a 46% overall response rate in relapsed/refractory T-cell lymphoma.

The phase 2 SANRECO trial met its primary end point, with 88% of this polycythemia vera population achieving a response with divesiran vs 19% with placebo.

Additional work is needed on a “significant population that develops lung cancer without a tobacco history,” according to Edward S. Kim, MD, MBA.

Age of 35 years or older, stage III/IV disease, and nondysgerminoma histology were linked with worse cancer-specific survival in malignant ovarian germ cell tumors.

Ami Shah, MD, Megan Kruse, MD, and Ruta Rao, MD, discuss DESTINY-Breast09, -11, and -05 data on trastuzumab deruxtecan in HER2-positive breast cancer.

The FDA did not highlight any concerns regarding the clinical or nonclinical data or safety profile of 177Lu-edoterotide.

City of Hope’s national clinical trials model can activate a study across a network of 40 sites in 4 states within 90 days, according to Edward Kim, MD, MBA.

The FDA granted fast track designation to BI-1808 plus pembrolizumab, which produced a 24% confirmed ORR in pretreated platinum-resistant ovarian cancer.

Patrick Borgen, MD built Brooklyn's breast cancer program from 47 patients to 8000. Now he and Joshua Feinberg, MD discuss what surgery looks like next.

Two pharmacy specialists discuss real-world data and clinical trial findings on the use of CAR T-cell therapy for pediatric patients with hematologic cancers.

Joshua Richter, MD, and Marco Davila, MD, PhD, focused on real-world CAR T-cell therapy outcomes in multiple myeloma.

Kim Stravers, an end-of-life doula and educator, outlined how training and certification standards vary across end-of-life doula organizations.

Goutham Vemana, MD, discussed navigating regional access logistics, insurance coverage, and patient assistance programs to deliver intravesical gemcitabine in NMIBC.

Joshua Richter, MD, and Marco Davila, MD, PhD, discussed what are some optimal candidates for CAR T-cell therapy in multiple myeloma.

Updated results from the phase 2 ELIANA trial support tisa-cel as definitive therapy for pediatric and young adult patients with relapsed/refractory B-ALL.

Goutham Vemana, MD, explained how the intravesical system provides continuous treatment exposure, deeper bladder penetration, and zero systemic absorption.

Allegheny Health Network Department of Urology is offering a gemcitabine intravesical system to provide the therapy for BCG-unresponsive NMIBC.

In a phase 1b/2 trial, epcoritamab plus bendamustine/rituximab produced a 96% complete response rate in patients with untreated follicular lymphoma.

Joshua Richter, MD, and Marco Davila, MD, PhD, weighed in on sequencing CAR T-cell therapy and bispecifics in multiple myeloma.

Kim Stravers, an end-of-life doula, discussed how she helps patients assert autonomy over end-of-life medical decisions, including pain management preferences.